Crizotinib in MET Deregulated or ROS1 Rearranged Pretreated Non-Small-Cell Lung Cancer (METROS): A Phase II, Prospective, Multicentre, Two-Arms Trial
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-19-0994
Full Text
Open PDFAbstract
Available in full text
Date
August 15, 2019
Authors
Publisher
American Association for Cancer Research (AACR)